Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC
- PMID: 41015516
- DOI: 10.1016/S0140-6736(25)01236-X
Ivonescimab versus pembrolizumab in PD-L1-positive NSCLC
Conflict of interest statement
We declare no competing interests.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
